Who are Glucocorticoid combination therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rapid-tapering glucocorticoids + Inebilizumab, Slow-tapering glucocorticoids + Inebilizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glucocorticoid-combination-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Glucocorticoid combination therapy — Competitive Intelligence Brief

Glucocorticoid combination therapy (Glucocorticoid combination therapy) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glucocorticoid combination. Area: Immunology, Rheumatology, Inflammatory diseases.

marketed Glucocorticoid combination Glucocorticoid receptor (GR) Immunology, Rheumatology, Inflammatory diseases Small molecule Live · refreshed every 30 min

Target snapshot

Glucocorticoid combination therapy (Glucocorticoid combination therapy) — Southeast University, China. Glucocorticoid combination therapy suppresses immune and inflammatory responses by binding to glucocorticoid receptors and modulating cytokine production and immune cell activation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Glucocorticoid combination therapy TARGET	Glucocorticoid combination therapy	Southeast University, China	marketed	Glucocorticoid combination	Glucocorticoid receptor (GR)
Rapid-tapering glucocorticoids + Inebilizumab	Rapid-tapering glucocorticoids + Inebilizumab	Tianjin Medical University General Hospital	phase 3	Monoclonal antibody + Glucocorticoid combination	BDCA-2 (on pDCs) + Glucocorticoid receptor
Slow-tapering glucocorticoids + Inebilizumab	Slow-tapering glucocorticoids + Inebilizumab	Tianjin Medical University General Hospital	phase 3	Monoclonal antibody + Glucocorticoid combination	BDCA-2 (CD320) on plasmacytoid dendritic cells; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glucocorticoid combination class)

Southeast University, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glucocorticoid combination therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/glucocorticoid-combination-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab